Frontier IP Group PLC (AIM:FIPP) says its portfolio is maturing well as several investee companies made significant progress during the second half of 2024, despite challenging conditions for early-stage technology firms and AIM-quoted stocks. Progress includes a €25 million raise by 2D Photonics, backed by Sony and NATO.
Solvonis Therapeutics PLC (LSE:SVNS) has cleared a key hurdle with the European Patent Office for its PTSD drug candidate. The ruling strengthens IP protection ahead of further development.
Reabold Resources PLC (AIM:RBD) is simplifying its stake in Italy’s Colle Santo gas project with a new deal through LN Energy. Staged payments include $10.5 million if a concession is granted, plus a 4% net profit interest.
Ariana Resources PLC (AIM:AAU) is raising £1.15 million through a placing and subscription to fund exploration and feasibility work at Dokwe. Directors are taking part, and the cash will cover costs through to July.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has landed over £430,000 to support gene therapy trials aimed at slowing ageing in dogs. The study will test its SIRT6 treatment on older animals over a 12-month period.
